Fig. 2: JK07 HER3 Antagonism Functional Assessment.
From: Preferential HER4 stimulation preserves neuregulin-induced improvement of myocardial function
A HER2/HER4 dimerization in U2OS HER2/HER4 dimerization cell lines. B In vitro proliferation assay evaluating JK07 activity in promoting cancer cell growth (NCI-N87, MCF07, RT-11D and T47D) driven by the HER3 signaling pathway. Results are representative of three independent experiments. C Evaluation of JK07 in a subcutaneous FaDu carcinoma xenograft model in NOD/SCID mice. Results were statistically significant at Day 21 for HER3 antagonistic antibody (p < 0.001), JK07 1 mg/kg (p < 0.05), and JK07 10 mg/kg (p < 0.001).
